FDA set to open com­ments on AI use in phar­ma man­u­fac­tur­ing

The FDA wants to know what peo­ple think about the use of AI in the phar­ma man­u­fac­tur­ing space.

Ac­cord­ing to a pub­lic in­spec­tion doc­u­ment, the FDA plans to pub­lish a re­quest for in­for­ma­tion no­tice on Wednes­day, aim­ing to gath­er pub­lic com­ments on “emerg­ing and ad­vanced” man­u­fac­tur­ing tech, specif­i­cal­ly in ar­ti­fi­cial in­tel­li­gence’s use in phar­ma man­u­fac­tur­ing.

The pa­per will lay out “ar­eas for con­sid­er­a­tions and pol­i­cy de­vel­op­ment” from the Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) sur­round­ing AI in phar­ma­ceu­ti­cal man­u­fac­tur­ing. The pa­per is meant to en­cour­age and gath­er feed­back from the pub­lic, peo­ple in the in­dus­try, as well as CDER and the Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER